|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boulay JL, Mild G, Lowy A, Reuter J,
Lagrange M, Terracciano L, Laffer U, Herrmann R and Rochlitz C:
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy
in patients with colorectal cancer. Br J Cancer. 87:630–634. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alhopuro P, Alazzouzi H, Sammalkorpi H,
Dávalos V, Salovaara R, Hemminki A, Järvinen H, Mecklin JP,
Schwartz S Jr, Aaltonen LA, et al: SMAD4 levels and response to
5-fluorouracil in colorectal cancer. Clin Cancer Res. 11:6311–6316.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahn BK, Jang SH, Paik SS and Lee KH: Smad4
may help to identify a subset of colorectal cancer patients with
early recurrence after curative therapy. Hepatogastroenterology.
58:1933–1936. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kawakami M, Yamaguchi T, Takahashi K,
Matsumoto H, Yasutome M, Horiguchi S, Hayashi Y, Funata N and Mori
T: Assessment of SMAD4, p53, and Ki-67 alterations as a predictor
of liver metastasis in human colorectal cancer. Surg Today.
40:245–250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baraniskin A, Munding J, Schulmann K,
Meier D, Porschen R, Arkenau HT, Graeven U, Schmiegel W, Tannapfel
A and Reinacher-Schick A: Prognostic value of reduced SMAD4
expression in patients with metastatic colorectal cancer under
oxaliplatin-containing chemotherapy: A translational study of the
AIO Colorectal Study Group. Clin Colorectal Cancer. 10:24–29. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Papageorgis P, Cheng K, Ozturk S, Gong Y,
Lambert AW, Abdolmaleky HM, Zhou JR and Thiagalingam S: Smad4
inactivation promotes malignancy and drug resistance of colon
cancer. Cancer Res. 71:998–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roth AD, Delorenzi M, Tejpar S, Yan P,
Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D,
et al: Integrated analysis of molecular and clinical prognostic
factors in stage II/III colon cancer. J Natl Cancer Inst.
104:1635–1646. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang B, Zhang B, Chen X, Bae S, Singh K,
Washington MK and Datta PK: Loss of Smad4 in colorectal cancer
induces resistance to 5-fluorouracil through activating Akt
pathway. Br J Cancer. 110:946–957. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang B, Halder SK, Kashikar ND, Cho YJ,
Datta A, Gorden DL and Datta PK: Antimetastatic role of Smad4
signaling in colorectal cancer. Gastroenterology.
138:969.e1-3–980.e1-3. 2010. View Article : Google Scholar
|
|
11
|
Halder SK, Beauchamp RD and Datta PK:
Smad7 induces tumorigenicity by blocking TGF-beta-induced growth
inhibition and apoptosis. Exp Cell Res. 307:231–246. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Halder SK, Beauchamp RD and Datta PK: A
specific inhibitor of TGF-beta receptor kinase, SB-431542, as a
potent antitumor agent for human cancers. Neoplasia. 7:509–521.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fanciullino R, Giacometti S, Mercier C,
Aubert C, Blanquicett C, Piccerelle P and Ciccolini J: In vitro and
in vivo reversal of resistance to 5-fluorouracil in colorectal
cancer cells with a novel stealth double-liposomal formulation. Br
J Cancer. 97:919–926. 2007.PubMed/NCBI
|
|
14
|
Wagner M, Roh V, Strehlen M, Laemmle A,
Stroka D, Egger B, Trochsler M, Hunt KK, Candinas D and Vorburger
SA: Effective treatment of advanced colorectal cancer by rapamycin
and 5-FU/oxaliplatin monitored by TIMP-1. J Gastrointest Surg.
13:1781–1790. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
O'Connor DS, Wall NR, Porter AC and
Altieri DC: A p34cdc2 survival checkpoint in cancer.
Cancer Cell. 2:43–54. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O'Connor DS, Grossman D, Plescia J, Li F,
Zhang H, Villa A, Tognin S, Marchisio PC and Altieri DC: Regulation
of apoptosis at cell division by p34cdc2 phosphorylation
of survivin. Proc Natl Acad Sci USA. 97:13103–13107. 2000.
View Article : Google Scholar
|
|
18
|
Chen Q and Li W, Wan Y, Xia X, Wu Q, Chen
Y, Lai Z, Yu C and Li W: Amplified in breast cancer 1 enhances
human cholangiocarcinoma growth and chemoresistance by simultaneous
activation of Akt and Nrf2 pathways. Hepatology. 55:1820–1829.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chao JI, Su WC and Liu HF: Baicalein
induces cancer cell death and proliferation retardation by the
inhibition of CDC2 kinase and survivin associated with opposite
role of p38 mitogen-activated protein kinase and AKT. Mol Cancer
Ther. 6:3039–3048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar
|
|
21
|
Cancer Genome Atlas N; Cancer Genome Atlas
Network: Comprehensive molecular characterization of human colon
and rectal cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Freeman TJ, Smith JJ, Chen X, Washington
MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG and
Beauchamp RD: Smad4-mediated signaling inhibits intestinal
neoplasia by inhibiting expression of β-catenin. Gastroenterology.
142:562–571. e5622012. View Article : Google Scholar
|
|
23
|
Kodach LL, Bos CL, Durán N, Peppelenbosch
MP, Ferreira CV and Hardwick JC: Violacein synergistically
increases 5-fluorouracil cytotoxicity, induces apoptosis and
inhibits Akt-mediated signal transduction in human colorectal
cancer cells. Carcinogenesis. 27:508–516. 2006. View Article : Google Scholar
|
|
24
|
Jeung HC, Che XF, Haraguchi M, Zhao HY,
Furukawa T, Gotanda T, Zheng CL, Tsuneyoshi K, Sumizawa T, Roh JK,
et al: Protection against DNA damage-induced apoptosis by the
angiogenic factor thymidine phosphorylase. FEBS Lett.
580:1294–1302. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng G, Xiong Y, Yi S, Zhang W, Peng B,
Zhang Q and He Z: 14-3-3σ regulation by p53 mediates a chemotherapy
response to 5-fluorouracil in MCF-7 breast cancer cells via Akt
inactivation. FEBS Lett. 586:163–168. 2012. View Article : Google Scholar
|
|
27
|
Knuefermann C, Lu Y, Liu B, Jin W, Liang
K, Wu L, Schmidt M, Mills GB, Mendelsohn J and Fan Z:
HER2/PI-3K/Akt activation leads to a multidrug resistance in human
breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jin W, Wu L, Liang K, Liu B, Lu Y and Fan
Z: Roles of the PI-3K and MEK pathways in Ras-mediated
chemoresistance in breast cancer cells. Br J Cancer. 89:185–191.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Taiyoh H, Kubota T, Fujiwara H, Matsumura
A, Murayama Y, Okamoto K, Ichikawa D, Ochiai T, Nakamura T,
Matsumoto K, et al: NK4 gene expression enhances
5-fluorouracil-induced apoptosis of murine colon cancer cells.
Anticancer Res. 31:2217–2224. 2011.PubMed/NCBI
|
|
30
|
Wang X, Martindale JL and Holbrook NJ:
Requirement for ERK activation in cisplatin-induced apoptosis. J
Biol Chem. 275:39435–39443. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Woessmann W, Chen X and Borkhardt A:
Ras-mediated activation of ERK by cisplatin induces cell death
independently of p53 in osteosarcoma and neuroblastoma cell lines.
Cancer Chemother Pharmacol. 50:397–404. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Basu A and Tu H: Activation of ERK during
DNA damage-induced apoptosis involves protein kinase Cdelta.
Biochem Biophys Res Commun. 334:1068–1073. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hernandez JM, Farma JM, Coppola D, Hakam
A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ and Shibata D:
Expression of the antiapoptotic protein survivin in colon cancer.
Clin Colorectal Cancer. 10:188–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Noda T, Nagano H, Takemasa I, Yoshioka S,
Murakami M, Wada H, Kobayashi S, Marubashi S, Takeda Y, Dono K, et
al: Activation of Wnt/beta-catenin signalling pathway induces
chemoresistance to interferon-alpha/5-fluorouracil combination
therapy for hepatocellular carcinoma. Br J Cancer. 100:1647–1658.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guo X, Goessl E, Jin G, Collie-Duguid ES,
Cassidy J, Wang W and O'Brien V: Cell cycle perturbation and
acquired 5-fluoro-uracil chemoresistance. Anticancer Res. 28:9–14.
2008.PubMed/NCBI
|
|
36
|
Gavin EJ, Song B, Wang Y, Xi Y and Ju J:
Reduction of Orc6 expression sensitizes human colon cancer cells to
5-fluorouracil and cisplatin. PLoS One. 3:e40542008. View Article : Google Scholar : PubMed/NCBI
|
